CRISPR Invested Capital Average Trend from 2010 to 2022

CRSP
 Stock
  

USD 78.87  3.74  4.98%   

CRISPR Therapeutics Invested Capital Average yearly trend continues to be very stable with very little volatility. Invested Capital Average is likely to grow to about 1.6 B this year. During the period from 2010 to 2022, CRISPR Therapeutics Invested Capital Average quarterly data regression pattern had range of 1,596,009,046 and median of  14,183,000. CRISPR Therapeutics Operating Income is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Operating Income of 373.53 Million. As of 10th of August 2022, Revenues is likely to grow to about 987.2 M, while Weighted Average Shares is likely to drop about 62.1 M.
  
Check CRISPR Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CRISPR main balance sheet or income statement drivers, such as Consolidated Income of 407.5 M, Earning Before Interest and Taxes EBIT of 409.5 M or Gross Profit of 987.2 M, as well as many exotic indicators such as Asset Turnover of 0.38, Book Value per Share of 34.09 or Current Ratio of 19.3. CRISPR financial statements analysis is a perfect complement when working with CRISPR Therapeutics Valuation or Volatility modules. It can also supplement CRISPR Therapeutics' financial leverage analysis and stock options assessment as well as various CRISPR Therapeutics Technical models . Continue to the analysis of CRISPR Therapeutics Correlation against competitors.

CRISPR Invested Capital Average Breakdown

Showing smoothed Invested Capital Average of CRISPR Therapeutics AG with missing and latest data points interpolated. Average invested capital value for the period used in the calculation of [ROIC]; and derived from [InvCap]. Invested capital is an input into the calculation of [ROIC]; and is calculated as: Total Debt plus Total Assets minus Goodwill and Intangible Assets minus Cash and Equivalents minus Current Liabilities. Please note this calculation method is subject to change.CRISPR Therapeutics' Invested Capital Average historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CRISPR Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Invested Capital Average10 Years Trend
Increasing
Slightly volatile
   Invested Capital Average   
Share
       Timeline  

CRISPR Invested Capital Average Regression Statistics

Arithmetic Mean 275,219,177
Geometric Mean 39,491,630
Coefficient Of Variation 206.60
Mean Deviation 393,213,195
Median 14,183,000
Standard Deviation 568,597,744
Range 1,596,009,046
R-Value 0.68
R-Squared 0.47
Significance 0.009981
Slope 99,814,584

CRISPR Invested Capital Average History

201617.2 M
201713.3 M
20185.8 M
201974.9 M
2020295.1 M
20211.5 B
20221.6 B

About CRISPR Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include CRISPR Therapeutics income statement, its balance sheet, and the statement of cash flows. CRISPR Therapeutics investors use historical funamental indicators, such as CRISPR Therapeutics's Invested Capital Average, to determine how well the company is positioned to perform in the future. Although CRISPR Therapeutics investors may use each financial statement separately, they are all related. The changes in CRISPR Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CRISPR Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on CRISPR Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in CRISPR Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Invested Capital1.9 B2.1 B
Invested Capital Average1.5 B1.6 B
Market Capitalization5.8 B5.3 B
Working Capital2.3 B2.5 B
Average Assets2.6 B2.8 B
Average Equity2.3 B2.5 B
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. Its CRISPRCas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The companys lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patients hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Be your own money manager

Our tools can tell you how much better you can do entering a position in CRISPR Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Watchlist Optimization Now

   

Watchlist Optimization

Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
All  Next Launch Module

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with CRISPR Therapeutics

0.75BLUBellus Health Aggressive PushPairCorr
0.89MBRXMoleculin Biotech Earnings Call  TodayPairCorr

Moving against CRISPR Therapeutics

0.9BBIBrickell Biotech Earnings Call  TomorrowPairCorr
0.88INMInmed Pharmaceuticals Fiscal Year End 23rd of September 2022 PairCorr
0.52BLCMBellicum Pharma Comm Earnings Call  TodayPairCorr
The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of CRISPR Therapeutics Correlation against competitors. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.9 B
Quarterly Revenue Growth YOY
-1.0
Return On Assets
-0.15
Return On Equity
-0.27
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.